The Prognostic Impact of Body Composition for Locally Advanced Breast Cancer Patients Who Received Neoadjuvant Chemotherapy.
body composition
breast neoplasm
computed tomography
obesity
pathologic complete response
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
04 Feb 2021
04 Feb 2021
Historique:
received:
07
12
2020
revised:
19
01
2021
accepted:
29
01
2021
entrez:
9
2
2021
pubmed:
10
2
2021
medline:
10
2
2021
Statut:
epublish
Résumé
Our previous study indicated that a high amount of visceral adipose tissue was associated with poor survival outcomes in patients with early breast cancer who received neoadjuvant chemotherapy. However, inconsistency was observed in the prognostic role of body composition in breast cancer treatment outcomes. In the present study, we aimed to validate our previous research by performing a comprehensive body composition analysis in patients with a standardized clinical background. We included 198 patients with stage III breast cancer who underwent neoadjuvant chemotherapy between January 2007 and June 2015. The impact of body composition on pathologic complete response and survival outcomes was determined. Body composition measurements had no significant effect on pathologic complete response. Survival analysis showed a low ratio of total visceral adipose tissue to subcutaneous adipose tissue (V/S ratio ≤ 34) was associated with shorter overall survival. A changepoint method determined that a V/S ratio cutoff of 34 maximized the difference in overall survival. Our study indicated the prognostic effect of body composition measurements in patients with locally advanced breast cancer compared to those with early breast cancer. Further investigation will be needed to clarify the biological mechanism underlying the association of V/S ratio with prognosis in locally advanced breast cancer.
Identifiants
pubmed: 33557032
pii: cancers13040608
doi: 10.3390/cancers13040608
pmc: PMC7913702
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Obesity (Silver Spring). 2019 Jun;27(6):997-1004
pubmed: 31021535
J Clin Oncol. 2008 Sep 1;26(25):4072-7
pubmed: 18757321
Clin Breast Cancer. 2016 Aug;16(4):e119-32
pubmed: 27067040
Breast. 2014 Jun;23(3):264-72
pubmed: 24530096
Obes Rev. 2012 Dec;13 Suppl 2:30-9
pubmed: 23107257
Diabetes Care. 2014;37(3):821-9
pubmed: 24186879
Eat Weight Disord. 2018 Apr;23(2):185-193
pubmed: 29492860
Breast Cancer Res Treat. 2016 Aug;159(1):109-18
pubmed: 27449492
PLoS One. 2017 Aug 31;12(8):e0183515
pubmed: 28859115
Cancer Med. 2016 Jan;5(1):41-8
pubmed: 26626021
Cancer Manag Res. 2019 Nov 12;11:9563-9569
pubmed: 32009814
Obesity (Silver Spring). 2010 May;18(5):879-83
pubmed: 20186138
Obesity (Silver Spring). 2007 Feb;15(2):370-6
pubmed: 17299110
Mol Aspects Med. 2013 Feb;34(1):59-70
pubmed: 23068072
Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):51-9
pubmed: 26545405
Obesity (Silver Spring). 2012 Oct;20(10):2101-6
pubmed: 22310233
Nutrition. 2020 Jul - Aug;75-76:110765
pubmed: 32279031
Int J Obes (Lond). 2013 Apr;37(4):620-2
pubmed: 22641063
JAMA Oncol. 2018 Jun 1;4(6):798-804
pubmed: 29621380
Am J Physiol Endocrinol Metab. 2000 May;278(5):E941-8
pubmed: 10780952
J Cancer Surviv. 2012 Dec;6(4):398-406
pubmed: 23054848
Breast Cancer Res Treat. 2020 Jan;179(2):435-443
pubmed: 31620935
Lancet Oncol. 2008 Jul;9(7):629-35
pubmed: 18539529
Breast Cancer Res Treat. 2015 Feb;150(1):127-39
pubmed: 25677740